An open label, single treatment, single period, single oral dose pharmacokinetic study of remogliflozin etabonate tablet 250 mg of Glenmark Pharmaceuticals Ltd., India in normal, healthy, adult, human male subjects under fasting condition.
Phase of Trial: Phase I
Latest Information Update: 16 Jan 2018
At a glance
- Drugs Remogliflozin etabonate (Primary)
- Indications Non-alcoholic steatohepatitis; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Glenmark Pharmaceuticals Ltd
- 08 Jan 2018 Status changed from not yet recruiting to completed.
- 12 Dec 2017 New trial record